A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
Clinical trial NCT03264547 · COMPLETED
Trial details
- NCT number
- NCT03264547
- Sponsor
- Japan Breast Cancer Research Group
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-28
- Primary completion
- 2024-12-31
- Enrollment
- 446
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.